Efficient Synthesis of HIV-1 Protease Inhibitors
- Summary
- Researchers at Purdue University have developed a new series of hexahydrofuropyran-derived HIV-1 protease inhibitors for treatment of HIV infection and AIDS. These inhibitors are novel and remarkably potent, similar to Darunavir, an FDA approved inhibitor also developed at Purdue. They also show excellent activity against multiple PI-resistant variants, superior to other FDA approved inhibitors.
- Technology Benefits
- High antiviral potencyEffective against wide range of variants
- Technology Application
- Medical/HealthcarePharmaceuticalsHIV/AIDS TreatmentDrug Development
- Detailed Technology Description
- Arun GhoshGhosh GroupPurdue Chemistry
- Countries
- United States
- Application No.
- 9,024,038
- *Abstract
-
- *Background
- HIV-1 protease inhibitors are critical components of highly active antiretroviral therapy (HAART). The HAART treatment regimens significantly reduced HIV/AIDS-related mortality. However, the rapid emergence of drug-resistant HIV-1 strains and the appearance of cross-resistance are severely limiting long-term treatment options.
- *IP Issue Date
- May 5, 2015
- *IP Type
- Cont-in-Part
- *Stage of Development
- Proof of Concept
- *Web Links
- Purdue Office of Technology CommercializationPurdueInnovation and EntrepreneurshipArun GhoshGhosh GroupPurdue Chemistry
- Country/Region
- USA
For more information, please click Here
